Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients

Maureen J. Donlin, Nathan A. Cannon, Rajeev Aurora et al. · 2010

Read Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients by Maureen J. Donlin, Nathan A. Cannon, Rajeev Aurora et al. (2010) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0009032.txt.

Description

Maureen Donlin and co-authors asked whether the hepatitis C virus's own genes shape treatment success, in PLOS ONE in 2010. Hepatitis C comes in six major genotypes. Patients with genotype 1 answer interferon therapy worse than others. African American patients respond only about half as often as Caucasian American patients.

The team compared whole viral genomes from patients of both groups. Differences scattered across the virus, not just in known hotspots, mattered. Viral genetics helped explain who cleared the virus on interferon. Reading the virus's genome could one day guide treatment choices for each patient.

Catalog record

CREATORMaureen J. Donlin, Nathan A. Cannon, Rajeev Aurora et al.
YEAR2010
COLLECTIONPAPERS
FORMATTXT
FILE SIZE47 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0009032

Browse the full library · About the Tower of Babel